AI assistant
Sending…
BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2022
Jun 2, 2022
31868_dirs_2022-06-02_a0854738-1e8b-4b15-8a9e-ffa4ca5ac7b4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2022-05-31
Reporting Person: LEVIN ALAN G (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-31 | Common Stock | A | 1138 | $9.31 | Acquired | 3197 | Direct |
Footnotes
F1: Shares of Common Stock issued to the reporting person in lieu of quarterly cash Board Member retainer of $11,250, prorated to $10,597.83 based on the increase in the annual retainer fee effective April 18, 2022.
More from BIOCRYST PHARMACEUTICALS INC
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Regulatory Filings
2026
May 4
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Proxy Solicitation & Information Statement
2026
Apr 23
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20